Current Studies | SeattleNTC

Current Studies

SeattleNTC is in the midst of four multisite research projects. 

Relmada Therapeutics

REL-1017 – A Chance to Overcome Depression

How the study works

REL-1017 is an oral tablet taken once daily at home. The Relight Clinical Research Study is for patients who are currently taking antidepressants. Participants in the clinical studies continue their current antidepressant and the investigational medication (REL-1017 or placebo, the inactive comparison pill) is taken in addition to their current medication. There are no costs associated to participating in the study. Participants do not have to pay for participation in a clinical research study. The Investigational medication, study supplies, study visits, and any test costs are covered as part of the study. Participants in the Relight studies may receive reimbursements for travel expenses.

Study duration

Relight will compare REL-1017 to placebo (inactive comparison pill) over 28 days. Participants who are enrolled in the trial receive REL-1017 or placebo for 28 days. Prior to receiving REL-1017 or placebo, participants undergo a screening period to ensure that they meet all study requirements.

The overall duration of the study, including screening and intervention period, will be approximately 50 days. The study is expected to enroll over 300 patients.

What happens when the clinical trial is over?

Participants have the opportunity to enroll in an Expanded Access Program if recommended by the treating physician. Participants can decide to withdraw from the study at any time.

You may be eligible to participate as a volunteer if you:

  • Are 18-65 years of age
  • Have been diagnosed with depression (Major Depressive Disorder)
  • Are currently feeling depressed and are taking an antidepressant

Please fill out the form below if you are interested in learning more about this study.

Interested in Research - Relmada
First
Last

The SAINT OLO Study

Are you living with major depressive disorder and struggling to find an effective treatment option?

The SAINT™ neuromodulation system may offer new hope.

We are recruiting adults 18 years and over for a new research program for major depression using the SAINT™ neuromodulation system, a breakthrough treatment for major depressive disorder (MDD).

  • To qualify for the study,
    • you must be 18 years or older
    • have a diagnosis of major depressive disorder
    • tried at least one antidepressant medication without satisfactory improvement

The prospective, multi-site program is called the Open-label Optimization trial, or OLO, designed to evaluate the safety and efficacy of the SAINT neuromodulation system for the treatment of major depression in a real-world setting.

The clinical research program will enroll up to 1,000 adults throughout the United States experiencing major depression who have failed to receive satisfactory improvement from a prior antidepressant medication. This is often referred to as “treatment-resistant major depression.”

What is SAINT?

The SAINT neuromodulation system is cutting-edge technology that uses non-invasive magnetic stimulation to target specific areas of the brain associated with depression. The SAINT approach has shown promising results in earlier studies, with fewer side effects than traditional medications and a faster onset of benefits.

What is the treatment like?

The clinical research program will involve a series of treatment sessions using the SAINT neuromodulation system over five consecutive days. First, you will undergo an MRI brain scan so doctors can locate the optimal location in your brain for neurostimulation. Once the MRI scan is completed, you will be scheduled for treatment with the SAINT neuromodulation system. This involves a series of 10 10-minute treatment sessions with 50-minute breaks each day for 5 days.

Throughout the trial, you will be cared for by our experienced team of professionals.

What are the benefits of SAINT?

SAINT neuromodulation treatment is a new, rapid-acting treatment option that is having a very positive impact on treating major depression. In completed clinical trials, treatment with SAINT for major depressive disorder has resulted in a significant reduction in depressive symptoms following the five-day treatment protocol. The SAINT treatment has shown high remission and response rates in both open-label studies, with approximately 80-90% of people achieving remission of depression symptoms following the five-day treatment protocol, and a double-blinded randomized controlled trial (RCT), where results reveal a 79% remission of depression symptoms in people in the active treatment arm following the protocol compared to 13% in the placebo treatment arm. These clinical results demonstrate that SAINT is safe and well tolerated and has the promise to be a reproducible, rapid and effective treatment option for people who have treatment-resistant major depression.

Is there a cost to participating in the clinical research program?

Yes, there is a patient cost for this breakthrough study.

To learn more:

If you are interested in participating in the clinical research program evaluating the SAINT neuromodulation system for major depressive disorder, please contact us at OLO@seattlentc.com or call 206-467-6300 ext. 5 and ask to speak about the SAINT study.

The COMP 006 Study

Exploring potential routes away from treatment-resistant depression.

Introducing the COMP 006 clinical study

Many people who receive antidepressant treatment for their depression do not get an adequate response to the medicines they are taking. If someone is taking two or more antidepressants and they are failing, this is sometimes referred to as treatment-resistant depression or TRD.

The COMP 006 study is looking into a new treatment approach for people with TRD using an investigational medicine given with psychological support. The study is suitable for people who have been diagnosed with major depression and are currently experiencing a recurrent or single episode of depression but that have not responded to antidepressant treatment.

You may be eligible to participate in a Compass Pathfinder study if you:

  • Are 18 years of age or older
  • Have been diagnosed with major depression (single or recurrent episodes)
  • Are experiencing treatment-resistant depression, defined as failing 2, 3 or 4 pharmacological treatments for your current episode of depression
  • Meet additional study criteria.

About the study

COMP006 is a three-part study which will last up to 62 weeks.

Participants will receive support from study clinicians to help them withdraw off any prohibited medications, including current antidepressants. Participants will be asked to remain off prohibited medications for parts of the study under close medical supervision.

Reimbursement for reasonable, out-of-pocket expenses for travel and other expenses may be available to qualified individuals.

Find out more

If you are interested in learning more about the COMP006 study, please contact us for an informal chat at compass@seattlentc.com or at 206-467-6300 ext. 5. We will ask you some brief questions and provide additional information about the study.

Expressing an interest does not oblige you in any way to take part in the study. So please, do get in touch if you want to find out more.

VNS Clinical Trial

The VNS study is investigating the efficacy of vagal nerve stimulation (VNS). We are currently recruiting for bipolar disorder. For more information on VNS, please reach out to us at recover@seattlentc.com

This research may have direct, positive impact on patient care and quality of life for years to come.

TMS TREATMENT

TMS TREATMENT

Gentle, non-invasive, FDA-approved treatment for depression, OCD, and others.

LEARN MORE

KETAMINE TREATMENTS

KETAMINE TREATMENTS

Now providing esketamine, IV ketamine, and ketamine assisted psychotherapy.

LEARN MORE

ECT TREATMENT

ECT TREATMENT

The most effective, life-saving treatment available for severe depression.

LEARN MORE

CLINICAL TRIALS

CLINICAL TRIALS

In addition to TMS, ECT, and ketamine, we offer clinical trial options.

LEARN MORE

ADDITIONAL THERAPIES

ADDITIONAL THERAPIES

If other treatments don’t work, we have interventions that may.

LEARN MORE

TMS TREATMENT

TMS TREATMENT

Gentle, non-invasive, FDA-approved treatment for depression, OCD, and others.

LEARN MORE

ECT TREATMENT

ECT TREATMENT

The most effective, life-saving treatment available for severe depression.

LEARN MORE

KETAMINE TREATMENTS

KETAMINE TREATMENTS

Now providing esketamine, IV ketamine, and ketamine assisted psychotherapy.

LEARN MORE

CLINICAL TRIALS

CLINICAL TRIALS

In addition to TMS, ECT, and ketamine, we offer clinical trial options.

LEARN MORE

WE HAVE THE EXPERTISE, PERSISTENCE AND COMPASSION
TO MAKE A DIFFERENCE FOR YOU.

Contact us at 206.467.6300